Can we stop cancer cells from evolving and developing drug resistance? British scientists take a leaf out of the HIV playbook
British scientists want to counter cancer by using an approach that worked for HIV and tuberculosis: by creating treatments to preclude cancer’s ability to become resistant to existing drugs and recur.
The drug discovery program, orchestrated by the Institute of Cancer Research (ICR) in London, will be launched at a facility in the British capital with an initial £75 million (roughly $85 million) injection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
